Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4865459
Max Phase: Preclinical
Molecular Formula: C21H16N2O2
Molecular Weight: 328.37
Molecule Type: Unknown
Associated Items:
ID: ALA4865459
Max Phase: Preclinical
Molecular Formula: C21H16N2O2
Molecular Weight: 328.37
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=C1CCCC2=C1C(c1ccncc1)C1=C(N2)c2ccccc2C1=O
Standard InChI: InChI=1S/C21H16N2O2/c24-16-7-3-6-15-18(16)17(12-8-10-22-11-9-12)19-20(23-15)13-4-1-2-5-14(13)21(19)25/h1-2,4-5,8-11,17,23H,3,6-7H2
Standard InChI Key: NETMGMZZMXIDFJ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 328.37 | Molecular Weight (Monoisotopic): 328.1212 | AlogP: 3.38 | #Rotatable Bonds: 1 |
Polar Surface Area: 59.06 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 5.03 | CX LogP: 1.69 | CX LogD: 1.69 |
Aromatic Rings: 2 | Heavy Atoms: 25 | QED Weighted: 0.87 | Np Likeness Score: -0.65 |
1. (2020) Inhibitors of GPR174 and Uses Thereof, |
2. (2020) Methods and Compositions for Treating Cancer, |
Source(1):